RxDoctor Payments Data

Sara Dentel

Family · Kings Mountain, NCNPI 1447899000

Payments from drug & device makers

$11,087in general payments, 2019–2025

Across 624 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$980
  • Pfizer$705
  • Bayer$566
  • Johnson & Johnson$518
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,79397%
  • Education$2943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,087 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,185
Medicare patients
124
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$54,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$50,839
Xigduo XrDapaglifloz Propaned/Metformin48$44,999
FarxigaDapagliflozin Propanediol24$32,027
VraylarCariprazine Hcl12$15,735
MounjaroTirzepatide11$11,281
QuliptaAtogepant11$10,894
MyrbetriqMirabegron20$10,745
NexletolBempedoic Acid12$9,554
TrulancePlecanatide13$7,474
ZtlidoLidocaine11$4,736
Lisdexamfetamine Dimesylate12$2,233
Budesonide DrBudesonide11$2,219
Albuterol Sulfate HfaAlbuterol Sulfate35$1,267
Pregabalin28$1,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,579$54,01247 claims
GSKTrelegy Ellipta$409$50,83963 claims
AstraZenecaFarxiga$980$32,02724 claims
AbbVieVraylar, Qulipta, Synthroid$1,827$27,62435 claims
Lilly USA, LLCMounjaro$495$11,28111 claims
Astellas Pharma US IncMyrbetriq$511$10,74520 claims
Esperion Therapeutics, Inc.Nexletol$209$9,55412 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$172$7,47413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Kings Mountain

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →